Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.79 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.79 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24735949 | 0.90 | ROCK2 (0.76) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL30692376 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL9883166 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL21412824 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL30607237 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL30607238 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL30607241 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil-M1 SCHEMBL21430354 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL22898365 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL20016619 | 0.87 | ROCK2 (0.82) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389035-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD, INC. | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389035-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885MYLK4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.